Tower Research Capital (TRC)’s TFF Pharmaceuticals, Inc. Common Stock TFFP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-1,948
| Closed | -$3.92K | – | 6125 |
|
|
2024
Q3 | $3.92K | Sell |
1,948
-2,984
| -61% | -$5.88K | ﹤0.01% | 4740 |
|
|
2024
Q2 | $8.19K | Buy |
4,932
+4,430
| +882% | +$11.6K | ﹤0.01% | 4380 |
|
|
2024
Q1 | $3.03K | Sell |
502
-870
| -63% | -$5.69K | ﹤0.01% | 4943 |
|
|
2023
Q4 | $9.63K | Buy |
1,372
+817
| +147% | +$6.35K | ﹤0.01% | 4364 |
|
|
2023
Q3 | $4.86K | Buy |
555
+81
| +17% | +$759 | ﹤0.01% | 4806 |
|
|
2023
Q2 | $5.57K | Sell |
474
-108
| -19% | -$1.55K | ﹤0.01% | 4814 |
|
|
2023
Q1 | $10K | Buy |
582
+393
| +208% | +$8.51K | ﹤0.01% | 4425 |
|
|
2022
Q4 | $5K | Buy |
189
+12
| +7% | +$569 | ﹤0.01% | 4934 |
|
|
2022
Q3 | $18K | Sell |
177
-13
| -7% | -$1.76K | ﹤0.01% | 4037 |
|
|
2022
Q2 | $27K | Sell |
190
-91
| -32% | -$12.7K | ﹤0.01% | 3489 |
|
|
2022
Q1 | $44K | Buy |
281
+229
| +440% | +$37K | ﹤0.01% | 2843 |
|
|
2021
Q4 | $11K | Buy |
+52
| New | +$10.1K | ﹤0.01% | 4478 |
|
|
2021
Q3 | – | Sell |
-211
| Closed | -$50K | – | 6272 |
|
|
2021
Q2 | $50K | Buy |
211
+175
| +486% | +$48K | ﹤0.01% | 3031 |
|
|
2021
Q1 | $12K | Buy |
36
+24
| +200% | +$9.76K | ﹤0.01% | 4287 |
|
|
2020
Q4 | $4K | Buy |
+12
| New | +$4.62K | ﹤0.01% | 4739 |
|
Other funds holding TFFP
Tower Research Capital (TRC)'s TFFP Position: Q4 2024 in Review
Tower Research Capital (TRC) sold out of TFF Pharmaceuticals, Inc. Common Stock (TFFP) in Q4 2024, closing a stake of 1,948 shares — an estimated $3.92K sold.
Tower Research Capital (TRC) first reported a position in TFFP in Q4 2020 and held it in 15 quarters. The position peaked at $50K in Q2 2021. 4 funds tracked by Wall St. Rank hold TFFP as of Q4 2024.
- Tower Research Capital (TRC) reported no remaining TFF Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Tower Research Capital (TRC) sold 1,948 TFF Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $3.92K.
- Tower Research Capital (TRC) first reported a position in TFF Pharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 15 quarters.
- Tower Research Capital (TRC)'s TFF Pharmaceuticals, Inc. Common Stock position peaked at $50K in Q2 2021.
- 4 funds tracked by Wall St. Rank held TFF Pharmaceuticals, Inc. Common Stock as of Q4 2024.
Based on Tower Research Capital (TRC)'s 13F filing for Q4 2024, filed 13 Feb 2025.